4D Molecular Therapeutics Inc (NAS:FDMT)
$ 25.15 0 (0%) Market Cap: 1.30 Bil Enterprise Value: 788.60 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 57/100

4D Molecular Therapeutics Inc Phase 1/2 Clinical Trial of 4D-150 for Wet AMD - Corporate Call Transcript

Nov 14, 2022 / 01:00PM GMT
Release Date Price: $13.49 (+7.83%)
Operator

Hello, ladies and gentlemen. Thank you for standing by, and welcome to 4D Molecular Therapeutics 4D-150 Phase I/II for Wet AMD Interim Clinical Data Conference Call. (Operator Instructions) As a reminder, today's call is being recorded.

With that, I will hand the call over to August Moretti, Chief Financial Officer, who will make introductory comments.

August J. Moretti
4D Molecular Therapeutics, Inc. - CFO

Thank you, operator, and welcome, everyone, to 4D Molecular Therapeutics' 4D-150 Phase I/II for Wet AMD Interim Clinical Data Conference Call. A press release describing the interim results from our Phase I/II clinical trial of 4D-150 in patients with wet AMD is accessible in the Investors section of the 4D Molecular Therapeutics website. And a recording of this webcast will be accessible on our website after completion of the call.

With me today are Dr. David Kirn, our Co-Founder and Chief Executive Officer; and Dr. Arshad Khanani, Managing Partner and Director of Clinical Research at Sierra Eye Associates and Clinical Associate

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot